by Igor Hajdukovic | Sep 16, 2026 | Uncategorized
In 2026, the most resilient medical practices aren’t those with the most expensive laser suites, but those that prioritize low-overhead, multi-specialty technology. You’ve likely felt the mounting pressure of rising overhead costs and the diminishing...
by Igor Hajdukovic | Sep 15, 2026 | Uncategorized
If you believe that any device marketed as a “fibroblast” tool is legally permitted for clinical use in Canada, you’re unintentionally risking your medical licence and your patients’ safety. Understanding the specific Health Canada requirements...
by Igor Hajdukovic | Sep 14, 2026 | Uncategorized
Investing in an unverified plasma pen might seem like a cost-effective entry into aesthetics, but it often exposes a Canadian practice to significant regulatory risk and inconsistent clinical outcomes. You’ve likely noticed the market is saturated with...
by Igor Hajdukovic | Sep 13, 2026 | Uncategorized
The distinction between a legal medical device and an illicit ‘fibroblast’ pen isn’t just a matter of marketing; it’s a matter of federal compliance that carries significant liability for Canadian practitioners. You’ve likely encountered...
by Igor Hajdukovic | Sep 12, 2026 | Uncategorized
Choosing a plasma device based on global marketing rather than specific Canadian regulatory standing can jeopardize a medical practice’s legal and clinical integrity. When evaluating the plaxpot vs medical plasma pen, the distinction isn’t merely...
by Igor Hajdukovic | Sep 11, 2026 | Uncategorized
In the high-stakes environment of medical aesthetics and ophthalmology, the distinction between a superficial spark and a controlled therapeutic arc is determined by the regulatory status of your equipment. You understand the frustration of distinguishing between...
